DanaLynneJohnsonMD

Pathology • Miami, FL

Forensic/Autopsy, Anatomic Pathology, Clinical Pathology

Physician

Join to view full profile

Are you Dr. Johnson?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 35 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
Number One On Bob Hope Rd (1851 Nw 10th Ave)
Miami-Dade County Medical Examiner Department
Miami, FL 33136
Phone+1 305-545-2425

Fax+1 804-827-1078
Is this information wrong?

Summary

Dr. Dana Johnson, MD is a board certified pathologist in Miami, Florida. She is currently licensed to practice medicine in Texas and Virginia.

Education & Training

Miami-Dade County Medical Examiner DepartmentFellowship, Forensic Pathology, 2013 - 2014
Virginia Commonwealth University Health SystemResidency, Pathology-Anatomic and Clinical, 2009 - 2013
University of Texas Southwestern Medical SchoolClass of 2009

Certifications & Licensure

TX State Medical License 2014 - 2024
VA State Medical License 2010 - 2024
American Board of Pathology Pathology - Anatomic/Pathology - Clinical
American Board of Pathology Pathology - Forensic

Publications & Presentations

PubMed

11 citations
Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody.
Simon A. Hinke, Anne M. Cieniewicz, Thomas Kirchner, Katharine D'Aquino, Rupesh Nanjunda, Jason Aligo, Robert Perkinson, Philip Cooper, Ken Boayke, Mark L. Chiu, Steve...> ;Molecular Metabolism. 2018 Feb 3
4 citations
The discovery and SAR of cyclopenta[b]furans as inhibitors of CCR2.
Michael P. Winters, Christopher A. Teleha, Fu-An Kang, David F. McComsey, John C. O’Neill, Cuifen Hou, Thomas Kirchner, Ping Wang, Dana L. Johnson, Zhihua Sui> ;Bioorganic & Medicinal Chemistry Letters. 2014 May 1
4 citations
Discovery and SAR of 5-aminooctahydrocyclopentapyrrole-3a-carboxamides as potent CCR2 antagonists.
Chaozhong Cai, Dave F. McComsey, Cuifen Hou, John C. O’Neill, Evan Opas, Sandra McKenney, Dana L. Johnson, Zhihua Sui> ;Bioorganic & Medicinal Chemistry Letters. 2014 Feb 15
16 citations
A novel series of N-(azetidin-3-yl)-2-(heteroarylamino)acetamide CCR2 antagonists.
Nalin L. Subasinghe, James C. Lanter, Thomas P. Markotan, Evan Opas, Sandra McKenney, Carl Crysler, Cuifen Hou, John C. O’Neill, Dana L. Johnson, Zhihua Sui> ;Bioorganic & Medicinal Chemistry Letters. 2013 Feb 15
3 citations
Novel 2-aminooctahydrocyclopentalene-3a-carboxamides as potent CCR2 antagonists.
Chaozhong Cai, Fu-An Kang, Cuifen Hou, John C. O’Neill, Evan Opas, Sandra McKenney, Dana L. Johnson, Zhihua Sui> ;Bioorganic & Medicinal Chemistry Letters. 2013 Jan 1
Matrix Metalloproteinase-9 Inhibition Reduces Inflammation and Improves Motility in Murine Models of Post-Operative Ileus.
Moore, B.A., Manthey, C.L., Johnson, D.L., Bauer, A.J.> ;Gastroenterology. 2011 Oct
GLP-2 receptor agonism ameliorates inflammation and gastrointestinal stasis in murine postoperative ileus.
Moore, B.A., Peffer, N., Pirone, A., Bassiri, A., Sague, S., Palmer, J.M., Johnson, D.L., Nesspor, T., Kliwinski, C., Hornby, P.J.> ;J Pharmacol Exp Ther. 2010 May
87 citations
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utili...
Carl L. Manthey, Dana L. Johnson, Carl R. Illig, Tuman Robert W, Zhao Zhou, Judith Baker, Margery A. Chaikin, Robert R. Donatelli, Carol F. Franks, Lee Zeng, Carl Crys...> ;Molecular Cancer Therapeutics. 2009 Nov 1
Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permea...
Santulli, R.J., Kinney, W.A., Ghosh, S., Decorte, B.L., Liu, L., Tuman, R.A., Zhou, Z., Huebert, N., Bursell, S.E., Clermont, A.C., Grant, M.B., Shaw, L.C., Mousa, S.A...> ;J Pharmacol Exp Ther. 2008 Mar
44 citations
Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
Anna C. Maroney, Juan J. Marugan, Tara M. Mezzasalma, Alexander N. Barnakov, Thomas Garrabrant, Larry E. Weaner, William J. Jones, Ludmila A. Barnakova, Holly K. Kobli...> ;Biochemistry. 2006 May 2
112 citations
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo
Holly K. Koblish, Shuyuan Zhao, Carol F. Franks, Robert R. Donatelli, Rose Tominovich, Louis V. LaFrance, Kristi A. Leonard, Joan Gushue, Daniel J. Parks, Raul R. Calv...> ;Molecular Cancer Therapeutics. 2006 Jan 1
30 citations
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors with Broad Antiproliferative Activ...
Chih Y. Ho, Donald Ludovici, Umar Maharoof, Jay Mei, Jan L. Sechler, Robert W. Tuman, Eric D. Strobel, Laura Andraka, Hwa-Kwo Yen, Gregory C. Leo, Jian Li, Harold R. A...> ;Journal of Medicinal Chemistry. 2005 Nov 22
11 citations
Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis.
Michael R. D'Andrea, Jay M. Mei, Tuman Robert W, Robert A. Galemmo, Dana L. Johnson> ;Molecular Cancer Therapeutics. 2005 Aug 1
Join now to see all